Dopamine-degrading activity of monoamine oxidase in locus coeruleus and dorsal raphe nucleus neurons. A histochemical study in the rat
- PMID: 9696061
- DOI: 10.1016/s0304-3940(98)00429-7
Dopamine-degrading activity of monoamine oxidase in locus coeruleus and dorsal raphe nucleus neurons. A histochemical study in the rat
Abstract
Dopamine-degrading activity of monoamine oxidase (MAO) was detected in the rat using a new histochemical method, with dopamine as the substrate. Our new method, designed to minimise the non-enzymatic oxidation of dopamine, was applied in combination with tyrosine hydroxylase (TH) and serotonin immunohistochemistry. We showed that the distribution pattern of MAO neurons was similar to that of TH-immunoreactive neurons (i.e. noradrenergic neurons) in the locus coeruleus (LC) and to that of serotonergic neurons in the dorsal raphe nucleus (DR). Since LC neurons form dopamine during noradrenaline biosynthesis, and DR neurons produce dopamine from exogenously administered L-dopa, our results indicate that dopamine produced in LC and DR neurons may be degraded, at least in part, by MAO.
Similar articles
-
Monoamine oxidase activity in noradrenaline neurons of the locus coeruleus of the rat. A double-labeling histochemical study.Brain Res. 1998 Dec 14;814(1-2):209-12. doi: 10.1016/s0006-8993(98)00939-1. Brain Res. 1998. PMID: 9838121
-
Dopamine-degrading activity of monoamine oxidase is not detected by histochemistry in neurons of the substantia nigra pars compacta of the rat.Brain Res. 1998 Nov 23;812(1-2):275-8. doi: 10.1016/s0006-8993(98)00983-4. Brain Res. 1998. PMID: 9813366
-
Histochemical study of dopamine-degrading monoamine oxidase activity in dopaminergic neurons of rat brain.Brain Res. 1999 Sep 25;842(2):491-5. doi: 10.1016/s0006-8993(99)01873-9. Brain Res. 1999. PMID: 10526149
-
Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.J Affect Disord. 1998 Dec;51(3):287-303. doi: 10.1016/s0165-0327(98)00225-0. J Affect Disord. 1998. PMID: 10333983 Review.
-
Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.Neurosci Biobehav Rev. 2013 Sep;37(8):1363-79. doi: 10.1016/j.neubiorev.2013.05.008. Epub 2013 May 24. Neurosci Biobehav Rev. 2013. PMID: 23707776 Review.
Cited by
-
The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.PLoS One. 2011;6(9):e24679. doi: 10.1371/journal.pone.0024679. Epub 2011 Sep 9. PLoS One. 2011. PMID: 21931808 Free PMC article.
-
What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum?Front Neurosci. 2016 Dec 15;10:575. doi: 10.3389/fnins.2016.00575. eCollection 2016. Front Neurosci. 2016. PMID: 28018168 Free PMC article. Review.
-
Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.J Neural Transm (Vienna). 2011 Dec;118(12):1727-32. doi: 10.1007/s00702-010-0570-9. Epub 2011 Jan 28. J Neural Transm (Vienna). 2011. PMID: 21274579
-
The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.Synapse. 2009 Jul;63(7):610-20. doi: 10.1002/syn.20630. Synapse. 2009. PMID: 19309758 Free PMC article.
-
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.J Neural Transm (Vienna). 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21. J Neural Transm (Vienna). 2011. PMID: 21253782
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources